Every Form 4 that SOPHiA GENETICS SA (SOPH) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow SOPH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SOPH filings page.
SOPHiA GENETICS SA Chief Medical Officer Philippe Menu reported new equity awards. He received a grant of 164,671 share options with an exercise price of $5.04 per share, and a separate grant of 112,936 ordinary shares in the form of restricted stock units.
The RSUs were granted under the company’s 2021 Equity Incentive Plan and vest over time, with 25% vesting on April 2, 2027 and the remaining 75% in equal quarterly installments through April 2, 2030, subject to continued service. The options vest as to 25% of the underlying ordinary shares on April 2, 2027, then in equal monthly installments through April 2, 2030, and expire on April 2, 2036. After these awards, Menu directly holds 112,936 ordinary shares and 164,671 share options from this filing.
Chief Scientific Officer Zhenyu Xu received new equity awards from SOPHiA GENETICS SA. On April 2, 2026, he was granted 112,936 ordinary shares as restricted stock units and a share option for 164,671 ordinary shares with a $5.04 exercise price.
The RSUs vest 25% on April 2, 2027, with the remaining 75% vesting in equal quarterly installments through April 2, 2030, subject to continued service. The option vests 25% on April 2, 2027, then in equal monthly installments through April 2, 2030, and expires on April 2, 2036. These are compensation-related grants rather than open-market purchases.
SOPHiA GENETICS SA Chief Executive Officer Jurgi Camblong reported equity compensation grants on April 2, 2026. He received 628,743 share options with an exercise price of $5.040 per ordinary share, expiring on April 2, 2036. He also received 431,211 restricted stock units (RSUs), each representing one ordinary share.
The RSUs vest with 25% on April 2, 2027, and the remaining 75% in equal quarterly installments through April 2, 2030, contingent on continued service. The options vest as to 25% on April 2, 2027, with the balance vesting in equal monthly installments through April 2, 2030. These are compensation-related awards, not open-market trades.
SOPHiA GENETICS SA Chief Sales Officer Kevin Puylaert reported equity awards consisting of stock options and restricted stock units as part of his compensation. He received options for 82,335 ordinary shares at an exercise price of $5.04 per share, expiring on April 2, 2036. These options vest 25% on April 2, 2027, then in equal monthly installments through April 2, 2030. He also received 56,468 restricted stock units, each representing one ordinary share, with 25% vesting on April 2, 2027 and the remaining 75% vesting in equal quarterly installments through April 2, 2030. These are awards, not open-market purchases or sales.
SOPHiA GENETICS SA disclosed that Chief Financial Officer George Cardoza received new equity awards. He was granted 164,671 share options with an exercise price of $5.04 per ordinary share, expiring on April 2, 2036, and 112,936 ordinary shares as restricted stock units (RSUs). These are compensation-related grants, not open-market purchases.
The RSUs vest 25% on April 2, 2027, with the remaining 75% vesting in equal quarterly installments through April 2, 2030. The share options vest 25% on April 2, 2027, then in equal monthly installments through April 2, 2030. After these grants, Cardoza directly holds 112,936 ordinary shares and options for 164,671 shares, aligning his compensation further with long-term company performance.
SOPHiA GENETICS SA Chief People Officer Manuela Valente received new equity awards tied to her role. She was granted share options for 104,790 ordinary shares at an exercise price of $5.04 per share, expiring on April 2, 2036. She also received 71,869 restricted stock units (RSUs), each representing one ordinary share upon vesting.
According to the vesting terms, 25% of the RSUs will vest on April 2, 2027, with the remaining 75% vesting in equal quarterly installments through April 2, 2030, conditioned on continued service. The share options vest as to 25% on April 2, 2027, then in equal monthly installments through April 2, 2030.
Van Well Daan reported acquisition or exercise transactions in this Form 4 filing.
SOPHiA GENETICS SA reported that Chief Legal Officer Daan Van Well received new equity compensation. He was granted options to buy 142,216 ordinary shares at $5.0400 per share, expiring on April 2, 2036. These options vest 25% on April 2, 2027, then in equal monthly installments through April 2, 2030.
He was also granted 97,536 restricted stock units (RSUs), each representing one ordinary share. For these RSUs, 25% vest on April 2, 2027, with the remaining 75% vesting in equal quarterly installments through April 2, 2030. These are compensation-related awards, not open-market share purchases or sales.
SOPHiA GENETICS SA Chief Sales Officer Kevin Puylaert had 3 Ordinary Shares sold in the open market at $4.71 per share. According to the disclosure, the sale was a “sell to cover” transaction to satisfy tax obligations from restricted stock units that vested on March 30, 2026, and was not a discretionary trade. Following this small tax-related sale, he holds 92,383 Ordinary Shares directly.
SOPHiA GENETICS SA Chief Legal Officer Daan Van Well sold 684 ordinary shares in an open-market transaction at a weighted average price of $4.7865 per share, within a $4.69–$4.87 range. The sale was made under a pre-established Rule 10b5-1 plan solely to cover tax obligations from restricted stock vesting. Following this tax-related sale, Van Well directly holds 261,238 ordinary shares.
SOPHiA GENETICS SA Chief Executive Officer Jurgi Camblong sold 4,486 ordinary shares in an open-market transaction at a weighted average price of $4.7727 per share. The sale was executed to cover tax obligations arising from restricted stock units that vested on March 18, 2026, under a pre-established Rule 10b5-1 trading plan and was not a discretionary trade. Following this transaction, Camblong directly holds 3,302,839 ordinary shares.
SOPHiA GENETICS SA Chief Medical Officer Philippe Menu sold 608 ordinary shares on March 19, 2026 in an open‑market transaction at a weighted average price of $4.7908 per share.
The footnotes state the sale was made to satisfy tax obligations from restricted stock units that vested on March 18, 2026 and was executed under a pre‑established Rule 10b5‑1 trading plan, meaning it was not a discretionary trade. Following the sale, Menu directly holds 173,616 shares.
SOPHiA GENETICS SA Chief Scientific Officer Xu Zhenyu reported an open-market sale of 608 Ordinary Shares at a weighted average price of $4.7813 per share.
The shares were sold to cover tax obligations arising from restricted stock units that vested on March 18, 2026, under a pre-established Rule 10b5-1 trading plan, meaning the trades were not discretionary. After this transaction, Xu directly holds 537,116 Ordinary Shares.
SOPHiA GENETICS SA Chief People Officer sells small block of shares for taxes
Chief People Officer Manuela Valente sold 380 Ordinary Shares of SOPHiA GENETICS SA on March 19, 2026 in an open-market transaction at a weighted average price of $4.7851 per share, with individual sale prices ranging from $4.68 to $4.87.
The shares were sold to satisfy tax obligations from restricted stock units that vested on March 18, 2026, under a pre-established Rule 10b5-1 trading plan and are described as non-discretionary trades. After this transaction, Valente directly holds 152,379 Ordinary Shares.
SOPHiA GENETICS SA President Ross Muken reported a small open‑market sale of 1,183 Ordinary Shares at a weighted average price of $4.7937 per share. According to the disclosure, the shares were sold to satisfy tax obligations arising from restricted stock units that vested on March 18, 2026, under a pre-established Rule 10b5-1 trading plan, meaning the transactions were pre-scheduled rather than discretionary. After these sales, Muken directly holds 271,910 Ordinary Shares.
SOPHiA GENETICS SA Chief Sales Officer Kevin Puylaert reported a small tax-related share sale. On March 18, 2026, he sold 33 Ordinary Shares at an average price of $4.76 per share and continued to hold 92,386 shares afterward.
The company states this was a “sell to cover” transaction executed in the open market solely to satisfy tax obligations tied to vesting restricted stock units, and it did not represent a discretionary trade.
SOPHiA GENETICS SA Chief Financial Officer George Cardoza reported an open-market sale of 774 Ordinary Shares on March 19, 2026 at a weighted average price of $4.7862 per share. The footnotes state this sale was made solely to satisfy tax withholding obligations from restricted stock units that vested on March 18, 2026, under a pre-established Rule 10b5-1 trading plan and was not a discretionary trade. After the transaction, Cardoza directly holds 184,858 Ordinary Shares, indicating this was a small, routine tax-related sale relative to his remaining position.